BioAtla Q4 net loss narrows on lower expenses

Overview

• US biotechnology firm's Q4 net loss narrowed year-over-year on lower operating expenses

• Company generated $2 mln in Q4 collaboration revenue, up from zero a year earlier

• BioAtla began formal process to monetize assets and implemented restructuring to cut costs

Result Drivers

• COST REDUCTIONS - Lower R&D and G&A expenses due to workforce reductions, program prioritization, and reduced stock-based compensation

• COLLABORATION REVENUE - $2 mln milestone payment from Context Therapeutics under license agreement contributed to Q4 revenue

• STRATEGIC REVIEW - Company initiated a formal process to monetize assets and is re-evaluating clinical program timing to preserve capital

Company press release: ID:nGNXc6X4lG

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "strong buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.